SEC Form 4 · accession 0001415889-16-007474
Niagen Bioscience, Inc. · NAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen R. Allen
Director
Period of report
Nov 16, 2016
Accepted (ET)
Nov 18, 2016 · 4:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001386570
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Options (right to buy)F1 | $2.605 | Nov 16, 2016 | A | 20,000 | A | Nov 16, 2017 | Nov 16, 2026 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1Options vest 100% on November 16, 2017.